A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed
to evaluate the safety, tolerability, and primary efficacy of IBI321 in participants with
locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does
not exist, has proven to be ineffective or intolerable.